Analysts Offer Predictions for ADAP Q1 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Adaptimmune Therapeutics in a research note issued on Tuesday, March 25th. Leerink Partnrs analyst J. Chang expects that the biotechnology company will earn ($0.10) per share for the quarter. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share. Leerink Partnrs also issued estimates for Adaptimmune Therapeutics’ Q2 2025 earnings at ($0.10) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.35) EPS and FY2026 earnings at ($0.11) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The company had revenue of $3.22 million during the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%.

Other analysts have also issued research reports about the stock. Wells Fargo & Company cut their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a research report on Friday, March 21st. StockNews.com initiated coverage on shares of Adaptimmune Therapeutics in a research note on Saturday. They issued a “buy” rating on the stock. Guggenheim reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a research report on Wednesday. Finally, Scotiabank reduced their target price on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating on the stock in a report on Friday, March 21st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1.93.

Adaptimmune Therapeutics Trading Down 6.4 %

Shares of ADAP opened at $0.21 on Friday. The business’s fifty day moving average is $0.51 and its 200-day moving average is $0.67. The firm has a market cap of $52.71 million, a price-to-earnings ratio of -0.94 and a beta of 2.52. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. Adaptimmune Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.55.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADAP. FMR LLC boosted its position in Adaptimmune Therapeutics by 3.0% during the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after purchasing an additional 50,419 shares during the period. Jane Street Group LLC grew its position in Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the last quarter. Virtu Financial LLC boosted its holdings in shares of Adaptimmune Therapeutics by 27.5% during the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares during the period. LPL Financial LLC boosted its holdings in Adaptimmune Therapeutics by 106.5% in the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 94,623 shares in the last quarter. Finally, Invesco Ltd. raised its stake in Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after buying an additional 28,526 shares in the last quarter. Hedge funds and other institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.